Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
复制标题
DOI：
10.1200/jco.1998.16.1.145
复制
发表时间：
1998-01-01
影响因子：
45.3
通讯作者：
Giaccone, G
中科院分区：
文献类型：
--
作者：
Curran, D;Sahmoud, T;Giaccone, G
目的：根据前瞻性收集的国际资料确定恶性胸膜间皮瘤患者的预后因素。患者和方法：自1984年10月至1993年10月，204例符合条件的成人恶性胸膜间皮瘤患者进入欧洲癌症研究和治疗组织(EORTC)连续5个前瞻性II期临床试验，以评估各种抗癌药物(米托蒽酮、硬膜外阿霉素、依托泊苷和紫杉醇)的疗效。结果：中位生存期为12.6个月，中位生存期为8.4个月。多因素分析显示，预后不良与预后状况差、白细胞计数高、间皮瘤可能/可能的组织学诊断、男性、组织学亚型肉瘤有关。考虑到这五个因素，将患者分为两组：预后良好组(1年生存率40%；95%可信区间[CI]30%~50%)和预后不良组(1年生存率12%；95%可信区间4%~20%)。结论：这些结果有助于通过选择更多同质性的患者组来设计新的胸膜间皮瘤临床试验。(C)1998年由美国临床肿瘤学会主办。
Purpose: Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data.Patients and Methods: From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model war used to assess 13 factors related to biology and disease history with respect to survival.Results: The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry, In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good-prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%).Conclusion: These results may help to design new clinical trials in pleural mesothelioma by selecting more homogenous groups of patients. (C) 1998 by American Society of Clinical Oncology.